Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 7, Pages 583-592Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2019.1632289
Keywords
Everolimus; pancreatic adenocarcinoma; mTOR
Categories
Funding
- U.S. Department of Health and Human Services, National Cancer Institute [2P30 CA023074]
Ask authors/readers for more resources
Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors'clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available